---
title: "BEAM.US (BEAM.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/BEAM.US/news.md"
symbol: "BEAM.US"
name: "BEAM.US"
parent: "https://longbridge.com/en/quote/BEAM.US.md"
datetime: "2026-05-20T20:26:07.908Z"
locales:
  - [en](https://longbridge.com/en/quote/BEAM.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/BEAM.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/BEAM.US/news.md)
---

# BEAM.US (BEAM.US) — Related News

### [Beam Therapeutics Eyes Sickle Cell BLA as Alpha-1 Gene-Editing Program Advances](https://longbridge.com/en/news/287103341.md)
*2026-05-20T18:04:26.000Z*
> Beam Therapeutics is advancing its base-editing platform for hematology and liver disease, with a potential biologics li

### [A Look At Beam Therapeutics (BEAM) Valuation As New BEACON Trial Data And Partnerships Draw Attention](https://longbridge.com/en/news/286662919.md)
*2026-05-17T06:12:12.000Z*
> Beam Therapeutics (BEAM) is presenting updated biomarker data from its BEACON trial, but its share price has recently de

### [Beam Therapeutics: Buy Rating Reaffirmed as Clinical Momentum Builds and $68 Price Target Remains Unchanged](https://longbridge.com/en/news/286397318.md)
*2026-05-14T10:15:31.000Z*
> Citi analyst Samantha Semenkow has reaffirmed a Buy rating for Beam Therapeutics (BEAM) stock, maintaining a $68 price t

### [Beam Therapeutics Supports AlphaDetect to Accelerate Detection of Alpha-1 | BEAM Stock News](https://longbridge.com/en/news/286289165.md)
*2026-05-13T07:50:26.000Z*
> Beam Therapeutics Supports AlphaDetect to Accelerate Detection of Alpha-1 | BEAM Stock News

### [IBA introduces AdaPTinsight XR, the next generation of CBCT imaging for image-guided proton therapy](https://longbridge.com/en/news/286200296.md)
*2026-05-13T05:01:28.000Z*
> IBA has launched AdaPTinsight XR, an advanced CBCT imaging solution for proton therapy, enhancing image-guided patient p

### [Will Beam Therapeutics' (BEAM) Revenue Surge, Pipeline Updates and Added Liquidity Change Its Narrative?](https://longbridge.com/en/news/285852499.md)
*2026-05-10T22:00:32.000Z*
> In Q1 2026, Beam Therapeutics reported a net loss of $94.32 million but a significant revenue increase to $31.74 million

### [Beam Therapeutics | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 31.74 M](https://longbridge.com/en/news/285537088.md)
*2026-05-07T11:11:23.000Z*
### [A Look At Beam Therapeutics (BEAM) Valuation After TIME Recognition And BEACON Trial Progress](https://longbridge.com/en/news/284974265.md)
*2026-05-02T18:00:32.000Z*
> Beam Therapeutics (BEAM) has gained attention after being recognized by TIME as one of the 10 Most Influential Health &